Court: No judicial reviews of warning letters; MedImmune to hire 100 in MD;

> The U.S. Court of Appeals for the District of Columbia has ruled that FDA warning letters "are not final agency actions;" companies therefore can't seek judicial review of them under the Administrative Procedures Act. Story (sub. req.)

> AstraZeneca's ($AZN) MedImmune biologics unit plans to add 100 employees to the staff of its manufacturing plant in Frederick, MD. Article

> Wilfried Hoffmann has joined Dublin-based Scale-up Systems as principal consultant, after 28 years with Pfizer ($PFE). Release

> India's High Court has directed that teams be formed to check pollution by pharmaceutical companies in Nalgonda, Andhra Pradesh, in response to villager complaints. Item

> Arnall Golden Gregory LLP announces the opening of a Miami, FL, office that will specialize in providing services to clients with global logistics and supply chain interests, including third-party logistics providers. Release

> Mustard Tree Instruments has launched a YouTube channel to spotlight its techniques and instruments for drug manufacturing QC; among them, Raman spectroscopy and raw material identity verification. Release | Channel

> NeoStem's ($NBS) cell therapy manufacturing division, Progenitor Cell Therapy, will provide contract manufacturing of Islet Sciences' microencapsulated insulin-producing, pancreatic islet cells. Release

> Nephron Pharmaceuticals will work with architect/developer ACi on a $313 million facility that aims for LEED silver certification. Story

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.